Medtronic (MDT) Getting Somewhat Positive News Coverage, Study Finds
Media stories about Medtronic (NYSE:MDT) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medtronic earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the medical technology company an impact score of 47.1138923069859 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Critical Survey: Arch Therapeutics (ARTH) versus Medtronic (MDT) (americanbankingnews.com)
- Head to Head Contrast: Medtronic (MDT) vs. Integer (ITGR) (americanbankingnews.com)
- Medtronic PLC (MDT) to Post Q3 2018 Earnings of $1.18 Per Share, Wedbush Forecasts (americanbankingnews.com)
- Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2018 (finance.yahoo.com)
- WishBone Medical Inc. Names Jean-Pierre Capdevielle as Chief Strategy Officer and Board Member (feeds.benzinga.com)
Several research analysts recently issued reports on the stock. Jefferies Group reissued a “buy” rating and set a $96.00 price target on shares of Medtronic in a report on Thursday, September 28th. SunTrust Banks reissued a “buy” rating and set a $96.00 price target on shares of Medtronic in a report on Monday, October 2nd. Zacks Investment Research cut shares of Medtronic from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Cowen set a $95.00 price target on shares of Medtronic and gave the stock a “buy” rating in a report on Tuesday, August 22nd. Finally, Stifel Nicolaus dropped their target price on shares of Medtronic from $91.00 to $83.00 and set a “hold” rating for the company in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the stock. Medtronic presently has a consensus rating of “Hold” and an average price target of $88.02.
Medtronic (NYSE MDT) traded up $0.50 during mid-day trading on Friday, hitting $81.07. 4,072,036 shares of the stock traded hands, compared to its average volume of 5,429,112. The firm has a market capitalization of $109,728.09, a price-to-earnings ratio of 17.47, a PEG ratio of 2.24 and a beta of 1.00. Medtronic has a twelve month low of $69.35 and a twelve month high of $89.72. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50.
Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. The firm had revenue of $7.05 billion for the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. Medtronic’s revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.12 earnings per share. sell-side analysts expect that Medtronic will post 4.77 EPS for the current year.
In other news, EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $78.03, for a total value of $1,248,480.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Omar Ishrak sold 140,407 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the completion of the sale, the chief executive officer now directly owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The disclosure for this sale can be found here. In the last three months, insiders sold 172,407 shares of company stock worth $13,974,223. Insiders own 0.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://theolympiareport.com/2017/12/10/medtronic-mdt-getting-somewhat-positive-news-coverage-study-finds.html.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.